Vera Therapeutics, Inc. (VERA)
| Previous close | 41.39 |
| Open | 40.23 |
| Bid | 39.69 x 100 |
| Ask | 40.23 x 200 |
| Day's range | 38.03 - 40.83 |
| 52-week range | 7.10 - 50.78 |
| Volume | |
| Avg. volume | 986,964 |
| Market cap | 2.185B |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.01 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 50.00 |
GlobeNewswireVera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentTopline 96-week data from ORIGIN 2 trial expected in Q4 2024Pivotal Phase 3 ORIGIN 3 trial estimated to complete enrollment for primary endpoint in Q3 2024; topline data expected in 1H 2025Completed $287.5 million financing, further strengthening the Company’s balance sheet BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Vera The
- GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,000 shares of Class A common stock and restricted stock units (RSUs) for 7,500 shares of Class A common stock to three new employees under Vera’s 2024 Inducement Plan (the Inducement Plan). Vera also announced that on May 6, 2024, the
Simply Wall St.Vera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock continues to impress, up 5.0% over last week
Key Insights Significantly high institutional ownership implies Vera Therapeutics' stock price is sensitive to their...
